Authors

• Sabrina Collins
• Meredith McKean (ORCID: https://orcid.org/0000-0003-0944-7418)
• Inderjit Mehmi (ORCID: https://orcid.org/0000-0002-2253-2206)
• John M. Kirkwood (ORCID: https://orcid.org/0000-0002-3570-4476)
• Joanna Kolodney
• Shining Wang
• Marina T. Lewis
• Rachel Roberts‐Thomson
• Xavier Parot
• C. Lance Cowey (ORCID: https://orcid.org/0000-0001-8597-8486)
• James Strauss (ORCID: https://orcid.org/0000-0001-6414-6998)
• Gregory A. Daniels (ORCID: https://orcid.org/0000-0001-9087-8009)
• Cheryl Li
• Eric J. Whitman
• David Gill (ORCID: https://orcid.org/0000-0002-7550-1761)
• David Sommerhalder (ORCID: https://orcid.org/0000-0002-7033-9064)
• Sajeve Thomas (ORCID: https://orcid.org/0000-0002-0925-3325)
• Gurpanna Saggu (ORCID: https://orcid.org/0000-0003-4829-7301)
• Melissa Johnson (ORCID: https://orcid.org/0000-0002-6913-6059)
• Raghad Abdul-Karim (ORCID: https://orcid.org/0000-0002-9350-7120)
• Tian Chen (ORCID: https://orcid.org/0000-0002-6629-0595)
• Yan Xing (ORCID: https://orcid.org/0000-0003-2150-1448)

Institutions

• Intermountain Healthcare (US)
• West Virginia University (US)
• South Texas College (US)
• AdventHealth Orlando (US)
• Texas Oncology (US)
• West Virginia University Hospitals (US)
• University of California San Diego (US)
• Mary Crowley Cancer Research Center (US)
• Queen Elizabeth Hospital (AU)
• Sarah Cannon (US)
• Angeles Clinic and Research Institute (US)
• City of Hope (US)
• UPMC Hillman Cancer Center (US)
• University of Pittsburgh Medical Center (US)
• Takeda (United States) (US)
• Atlantic Health System (US)

Publication Details

Journal

Frontiers in Oncology

Published

2025-12-08

DOI

https://doi.org/10.3389/fonc.2025.1620987

Primary Topic

Peptidase Inhibition and Analysis

Type

article

Field-Weighted Citation Impact

0.00

Funders

• Bristol-Myers Squibb
• Takeda Pharmaceuticals U.S.A.
• Regeneron Pharmaceuticals
• Springworks Therapeutics